Zafibral Drug Interactions

Care is required in administering ZAFIBRAL to patients receiving anti-coagulant therapy of the coumarin type. The dose of anticoagulant should be reduced by 50 percent initially and then titrated to the patient's needs. As BEZAFIBRATE improves glucose utilisation the action of antidiabetic medication, including insulin, may be potentiated. Hypoglycaemia has not been observed although increased monitoring of the glycaemic status may be warranted for a brief period after introduction of ZAFIBRAL.
Should combined therapy with an ion-exchange resin be considered necessary, there should be an interval of 2 hours between the intake of the resin and ZAFIBRAL, as the absorption of bezafibrate otherwise may be impaired. MAO inhibitors should not be administered with bezafibrate.
Since oestrogens may lead to a rise in lipid levels, the necessity of treatment with ZAFIBRAL in patients receiving oestrogens or oestrogen containing preparations should be considered on an individual basis.